Lioton (Heparin Sodium)

Heparin Sodium binds to antithrombin III, markedly increasing its ability to inhibit thrombin (factor IIa) and factor Xa. By blocking these key enzymes, the conversion of fibrinogen to fibrin is reduced, which interrupts clot formation and limits the growth of existing clots within the circulatory system.

The appropriate dose of Lioton is determined by the prescribing healthcare professional based on the patient’s condition, weight, renal function, and other clinical factors. Dosage regimens are individualized and should follow the prescriber’s instructions without deviation.

Safety data for Heparin Sodium in pregnancy and lactation are limited. It may be used when the potential benefit justifies the potential risk to the fetus or infant. Clinicians should evaluate each case carefully and discuss possible risks with the patient.

To request Lioton, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs), and required import documentation.

Lioton’s Heparin Sodium is an unfractionated heparin, offering rapid onset and reversible anticoagulation via protamine. Compared with low‑molecular‑weight heparins, it has a shorter half‑life and requires more frequent monitoring. Unlike vitamin K antagonists such as warfarin, it does not require routine INR testing but has a higher risk of heparin‑induced thrombocytopenia.

Lioton should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and avoid exposure to extreme temperatures that could compromise its stability.

Lioton is intended for cutaneous (topical) application. The prescribed amount is applied to the clean skin surface of the affected area, usually using a sterile swab or gauze. Follow the healthcare provider’s instructions regarding frequency and duration of use.

The most critical adverse events include heparin‑induced thrombocytopenia (HIT), which can paradoxically increase clot risk, and major bleeding that may be life‑threatening. Prompt recognition of unexplained bruising, sudden drops in platelet count, or excessive bleeding is essential.

Lioton is contraindicated in patients with active major bleeding, a known history of heparin‑induced thrombocytopenia, severe thrombocytopenia, or uncontrolled hypertension. It should also be avoided in individuals with hypersensitivity to heparin or any of the product’s excipients.